Advanced Heart Failure Symposium

時間: 114年7月26日(星期六) 13:45-17:00

地點: 高雄漢來大飯店 15 樓會展廳 (高雄市前金區成功一路 266 號)

Time	Topics	Speaker	Chair
13:45-13:50	Welcome Introduction and Keynote	李貽恒	
(5")			
13:50-14:10	Identifying the Patient with Advanced	陳柏升	李貽恒
(20")	Heart Failure: When to Refer?		
14:10-14:30	Strategies for Managing the Cardiogenic	吳韋璁	
(20")	Shock Patients		林宗憲
14:30-14:50	Temporary VAD for Cardiogenic Shock:	楊翔宇	
(20")	What to do Now? What to do Next?		
14:50-15:10	Patient Selection for LVAD	吳佳穎	
(20")			蔡宜廷
15:10-15:30	Long Term Care for LVAD	諶大中	
(20")			
15:30-15:50	Current Indication and Status for Heart	劉國聖	
(20")	Transplantation		許志新
15:50-16:10	Advances in Immunosuppression and	傅薰儀	
(20")	Rejection Management		
16:10-16:30	End-of-Life Care and Hospice in Advanced	王玟樺	謝宜璋
(20")	Heart Failure		
16:30-16:55	Panel Discussion	All	
(25")			
16:55-17:00	Closing Remarks	謝宜璋	
(5")			

Strategies for Managing the Cardiogenic Shock (CS) Patients

吳韋璁 醫師

摘要

Shock Team 啟動

組成多專科 Shock Team:重症、心臟科、心衰專科、介入心臟科、心臟外科等。使用標準化流程提升病人分流、治療與轉院效率。多中心資料顯示: Shock Team 能提升使用進階 hemodynamic 監測與 tMCS 的比率,降低 ICU 死亡率。

血流動力學監測

建議使用肺動脈導管(PAC)進行侵入性監測: 評估左/右/雙心室負荷型態與 cardiac index。

PAPi、CVP/PCWP 等指標協助風險分層與治療調整。

藥物治療策略

根據血壓與灌流狀態選擇最適合的 vasoactive agents:

目前沒有明確第一線用藥建議,但 Inopressors (如 norepinephrine)為首選。避免高劑量或長期使用導致心肌耗損。

使用最低有效劑量並搭配 diuretics 解決鬱血型 CS。

tMCS(暫時性機械循環支持)

裝置選擇須依據血流動力學需求與併發症風險評估。
DanGer Shock trial 顯示 microaxial pump 可改善 STEMI-CS 預後。
強調慎選適應症,避免濫用。

結語

以個人化、動態調整與跨科團隊合作為管理核心, Recognize/Rescue → Optimize → Stabilize → De-Escalation/Exit 」四階段照護模式。

Patient selection for LVAD

吳佳穎 醫師

This presentation will discuss patient selection for durable left ventricular assist device (LVAD) implantation in the management of advanced heart failure. With advancements in technology, LVADs have emerged as a life-saving therapy offering outcomes comparable to heart transplantation at five years post-implantation. However, optimal results depend heavily on appropriate patient selection. Key considerations include the INTERMACS classification as a standard guide for surgical indication, as well as the patient's socio-economic status and support system. Patients who are unable or unwilling to participate in their own care or lack adequate support may experience suboptimal outcomes.

Long term care for LVAD 左心室輔助器植入後的長期照護

隨著心衰竭治療的進步,左心室輔助器(LVAD)在末期心衰竭病人的角色日益重要,無論是作為橋接至移植(bridge to transplantation)或目的性治療(destination therapy),應用愈發普及。「心伴三號」(HeartMate 3)為目前使用最廣泛的連續流機型,其經臨床證實在血栓形成率與泵浦故障方面具明顯優勢。

左心室輔助器植入後病人的長期照護重點,涵蓋以下幾大核心面向:

- 左心室輔助器植入後病人的心衰用藥調整策略
- 抗凝治療的優化與調整策略
- 咸染預防與傷口管理(特別是導線出口處)
- 裝置功能監測與遠端追蹤應用
- 合併症管理:胃腸道出血、右心衰竭、泵内血栓等
- 心理社會支持與病患依從性促進
- 跨團隊整合照護的角色:內科、外科、感染科、復健及護理

同時也將簡要分享實際個案,討論心臟內外科醫師在門診與住院照護中應注意的細節。

關鍵詞: 左心室輔助器、心伴三號、長期照護、抗凝治療、裝置感染、心衰竭

Current Indication and Status for Heart Transplantation

劉國聖 醫師

Abstract

Heart transplant is still the gold standard treatment for end-stage heart failure, despite of the advancement of mechanical circulatory support. In this presentation, I will give an updated review on the current indications, results, and gaps in heart transplantation.

Advances in Immunosuppression and Rejection Management

傅薰儀醫師

Heart transplantation is a critical treatment for end-stage heart disease, but it carries the inherent risk of organ rejection, necessitating a delicate balance between preventing rejection and minimizing immunosuppression-related complications. The latest ISHLT Guidelines published in 2023 provides updated recommendations on immunosuppressive strategies, rejection surveillance, and the management of acute and chronic rejection in adult heart transplant recipients.

Recent innovations in immunosuppressant strategies and rejection management in heart transplantation have significantly advanced the field, offering improved outcomes for patients undergoing this complex procedure. The evolution of these strategies has been driven by a better understanding of the mechanisms behind both acute and chronic rejection, leading to more tailored and less invasive management protocols that aim to balance efficacy with minimal side effects.

Notable advancements include the introduction of personalized medicine approaches that leverage genetic and biomarker data to inform immunosuppressive regimens tailored to individual patient profiles. Innovative diagnostic techniques, such as cell-free DNA analysis and advanced imaging methods, have emerged to facilitate non-invasive monitoring of graft status, allowing for timely interventions that can significantly enhance patient outcomes.

Additionally, the integration of new classes of immunosuppressive agents, such as proliferation signal inhibitors, reflects an ongoing shift towards more sophisticated treatment modalities that address the specific needs of heart transplant recipients. However, the field faces several challenges, including patient adherence to complex medication regimens, the risk of infections associated with immunosuppression, and cardiovascular toxicities that can arise from long-term treatment. These factors complicate the management of immunosuppressive therapies, highlighting the need for continued research to develop safer and more effective strategies that minimize risks while maximizing graft survival.

As the landscape of heart transplantation continues to evolve, the focuses on personalized immunosuppression, improved diagnostic tools for rejection surveillance, and careful management of immunosuppression-related complications remain paramount to improving the overall quality of life for transplant recipients.

陳柏升醫師

職稱:

成大醫院內科部主治醫師

學歷:

成大臨床醫學研究所博士 成大醫學系

專長:

高血壓、心臟衰竭、心絞痛、心律不整、心臟超音波、重症照護

重要經歷

(現任)

成大醫學院臨床助理教授 成大醫院內科部內科重症加護功能分科主治醫師 (曾任)

美國哈佛大學 Brigham and Women's Hospital 心臟血管科研究員成大醫院內科部內科重症加護功能分科研究員成大醫院內科部心臟內科研究員成大醫院內科部心臟內科總醫師成大醫院內科部住院醫師成大醫院實習醫師

吳韋璁

現任職稱

高雄醫學大學附設中和紀念醫院心臟血管內科主治醫師 中國鋼鐵股份有限公司員工診所 心臟內科 特約醫師 中華民國心臟學會 心衰竭 委員

學歷

高雄醫學大學 醫學士後醫學系 高雄醫學大學 醫學研究所 碩士

經歷

高雄醫學大學附設中和紀念醫院 內科部住院醫師 高雄醫學大學附設中和紀念醫院 內科部總住院醫師 行政院衛生福利部恆春旅遊醫院 心臟內科主治醫師 枋寮醫療社團法人枋寮醫院 心臟內科主治醫師 高雄醫學大學附設中和紀念醫院心臟血管內科主治醫師

專科執照與學會

中華民國 內科專科醫師暨 內科專科指導醫師中華民國 心臟內科專科醫師暨 心臟內科專科指導醫師中華民國心臟學會 心臟血管介入專科醫師臺灣介入性心臟血管醫學會 會員中華民國心臟學會冠狀動脈旋磨術認證課程訓練證書中華民國心臟學會心臟衰竭急性後期整合照顧認證課程高雄市糖尿病共同照護網認證台灣睡眠醫學學會會員 暨睡眠專科醫師

吳佳穎 Chia-Ying (Joy) Wu

Born: 1st of Oct. 1990, Tainan, Taiwan (R.O.C.)

Address: 6F-3, No.509, Dehua Street., North Dist., Taichung City 404, Taiwan (R.O.C.)

Email: joywu1001@hotmail.com; 024942@tool.caaumed.org.tw

EDUCATION

Doctor of Medicine China Medical University 中國醫藥大學 2009-2016 Taichung, Taiwan

CERTIFICATION and TRAINING

Internship

China Medical University Hospital 中國醫藥大學附設醫院 2015-2016

Post-graduate year (PGY)

China Medical University Hospital 中國醫藥大學附設醫院 2016-2017

Residency and Fellowship

Cardiovascular Surgery Division, Surgical Department China Medical University Hospital 中國醫藥大學附設醫院 2017-2023

台灣外科醫學會專科醫師 台灣胸腔及心臟血管外科學會專科醫師 中華民國重症醫學會專科醫師 台灣血管外科學會專科醫師

PROFESSIONAL EXPERIENCE

Observer, exchange student

Pediatric surgery, Vienna General Hospital 2013 summer, 1 month Allgemeines Krankenhaus der Stadt Wien (AKH), Vienna, Austria

Observer

Surgical oncology department, MD Anderson Cancer Center 2014 autumn, 1 month Houston, Texas, USA

現職

Attending surgeon

Cardiovascular Surgery, China Medical University Hospital 中國醫藥大學附設醫院心臟血管外科主治醫師

諶大中

學經歷:

1988-09~1995-06 國立台灣大學醫學系(MD)

1997-07~2002-06 國立台灣大學附設台大醫院外科部住院醫師及總住院醫師

2008-10~2011-05 國立政治大學經營管理碩士,非營利組織管理組(EMBA-NPO)

2019-03~2019-04 加拿大英屬哥倫比亞大學聖保羅醫院 "經導管主動脈瓣膜置換手

術(TAVR)"專題進修

工作簡歷:

1995-10~1997-06 中華民國陸軍澎湖防衛司令部少尉軍醫官

1997-07~2002-06 國立台灣大學附設台大醫院外科部住院醫師及總住院醫師

2002-07~2007-06 佛教慈濟醫療財團法人大林慈濟醫院心臟外科主治醫師

2005-08~2007-06 佛教慈濟醫療財團法人大林慈濟醫院心臟外科主任

2007-07~2009-07 佛教慈濟醫療財團法人台北慈濟醫院外科加護病房主任

2010-08~2024-12 佛教慈濟醫療財團法人台北慈濟醫院開刀房主任

現職:

2007-07~ 佛教慈濟醫療財團法人台北慈濟醫院心臟外科主治醫師

2011-07~ 佛教慈濟醫療財團法人台北慈濟醫院心臟外科主任

學會及認證:

台灣胸腔及心臟血管外科醫學會心臟外科專科醫師及專科指導醫師

中華民國心臟學會心臟外科專科醫師及專科指導醫師

台灣血管外科醫學會專科醫師及專科指導醫師

行政院衛生福利部核定心臟摘取、移植手術施行醫師

行政院衛生福利部核定經導管主動脈瓣膜置換手術施行醫師

台灣胸腔及心臟血管外科醫學會機械手臂輔助心臟外科手術操作醫師

專業與趣:

經導管心臟辦膜手術、全內視鏡心臟辦膜手術、心衰竭治療及手術、心室輔助器手術、心臟移植、傳統心臟手術

Name: Liu, Kuo-Sheng (劉國聖)

Education:

1993-2000 Medical College of Chang Gung University, Taiwan

2009-2014 Graduate Institute of Mechanical Engineering, Chang Gung University, Taiwan

Employment Record:

Sep 2000 – Feb 2002	Military Service as Medical Doctor
July 2002 – June 2005	R1-R3, Department of Surgery, Linkou Chang Gung Memorial
	Hospital (CGMH)
July 2005 – June 2007	Fellow, Division of Thoracic & Cardiovascular Surgery, Linkou
CGMH	
July 2007 – June 2009	Attending Staff, Div. of Thoracic & Cardiovascular Surgery, Linkou
CGMH	
July 2009 – Dec 2009	Attending Staff, Div. of Thoracic & Cardiovascular Surgery, Xiamen
CGH	
Jan 2010 – now	Attending Staff, Div. of Thoracic & Cardiovascular Surgery, Linkou
CGMH	
April – May 2017	Visiting Surgeon, Cardiac Surgery, New York-Prebysterian/Columbia
	University Medical Center
July 2017 – now	Chief, Section of Cardiac Surgery, Linkou CGMH
April 2010	Lecturer of Surgery, Div. of Thoracic & Cardiovascular Surgery,
CGMH	
May 2011	Assistant Professor, Div. of Thoracic & Cardiovascular Surgery,
CGMH	
July 2017	Associate Professor, Div. of Thoracic & Cardiovascular Surgery,
CGMH	

Board Certifications:

- 1. Doctor License of Republic of China No.: 032540
- 2. The Surgical Association of the Republic of China, No.: 005426
- 3. Taiwan Society of Cardiology, No.: 042
- 4. Taiwan Association of Thoracic & Cardiovascular Surgery, No.: 320
- 5. Taiwan Society of Critical Care Medicine, No.: 01424
- 6. Taiwan Society for Vascular Surgery, No.: S00455



Hsun Yi Fu

Position	Attending physician	
Organization	National Taiwan University Hospital Hsin-Chu Branch	
Major Field	Cardiovascular surgery	
Education	Doctor of Medicine	
Professional Experience		
Honors & Awards		
Publications	Outcome of urgent desensitization in sensitized heart transplant recipients. Fu HY, Wang YC, Tsao CI, Yu SH, Chen YS, Chou HW, Chi NH, Wang CH, Hsu RB, Huang SC, Yu HY, Chou NK. J Formos Med Assoc. 2021 Jul 30:S0929-6646(21)00345-4.	
Short Bio (in 300 words)	2006 – 2012 National Taiwan University College of Medicine 2012 – 2013 Post Graduate Year, National Taiwan University Hospital 2013 – 2014 Department of Anesthesia, National Taiwan University Hospital 2014 – 2020 Department of Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital	